Patents Assigned to Antidote Therapeutics, Inc.
  • NOVEL NICOTINE DEGRADING ENZYME VARIANTS
    Publication number: 20230416697
    Abstract: Described are nicotine-degrading enzyme variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity relative to the wild-type NicA2 and NOX enzymes, compositions comprising the variants, and methods using them.
    Type: Application
    Filed: March 2, 2023
    Publication date: December 28, 2023
    Applicants: Antidote Therapeutics, Inc., Board of Regents, The University of Texas System
    Inventors: Matthew W. KALNIK, Thomas THISTED, Everett STONE, Charles C. REED, Max RODNICK-SMITH
  • NOVEL NICOTINE-BINDING ANTIBODIES
    Publication number: 20230089068
    Abstract: Described are novel nicotine-binding antibodies and methods of using them for treating nicotine addiction and/or facilitating smoking cessation, or for treating nicotine overdose or nicotine poisoning.
    Type: Application
    Filed: August 12, 2022
    Publication date: March 23, 2023
    Applicants: ANTIDOTE THERAPEUTICS, INC., BliNK BIOMEDICAL, Hennepin Healthcare Research Institute
    Inventors: Matthew W. KALNIK, Thomas THISTED, Nicola BELTRAMINELLI, Stéphanie FALLOT, Zuzana BIESOVA, Steve FULLER, Mark G. LeSAGE, Paul PENTEL
  • Nicotine degrading enzyme variants
    Patent number: 11597916
    Abstract: Described are nicotine-degrading enzyme variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity relative to the wild-type NicA2 and NOX enzymes, compositions comprising the variants, and methods using them.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: March 7, 2023
    Assignees: ANTIDOTE THERAPEUTICS, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Matthew W. Kalnik, Thomas Thisted, Everett Stone, Charles C. Reed, Max Rodnick-Smith
  • Nicotine-binding antibodies
    Patent number: 11440970
    Abstract: Described are novel nicotine-binding antibodies and methods of using them for treating nicotine addiction and/or facilitating smoking cessation, or for treating nicotine overdose or nicotine poisoning.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: September 13, 2022
    Assignees: ANTIDOTE THERAPEUTICS, INC., BliNK BIOMEDICAL, Hennepin Healthcare Research Institute
    Inventors: Matthew W. Kalnik, Thomas Thisted, Nicola Beltraminelli, Stéphanie Fallot, Zuzana Biesova, Steve Fuller, Mark G. Lesage, Paul Pentel
  • METHODS FOR IMPROVING CIRCULATION AND TREATING CARDIOVASCULAR DISEASE
    Publication number: 20220267474
    Abstract: Described are methods of treating cardiovascular diseases in smokers and/or subjects ingesting or consuming nicotine from other sources (e-cigarettes/vaping, smokeless tobacco, NRT, etc.
    Type: Application
    Filed: June 5, 2019
    Publication date: August 25, 2022
    Applicant: ANTIDOTE THERAPEUTICS, INC.
    Inventors: Matthew W. KALNIK, Thomas THISTED, Warren C. STERN
  • NOVEL NICOTINE DEGRADING ENZYME VARIANTS
    Publication number: 20220031814
    Abstract: Described are nicotine-degrading enzyme variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity relative to the wild-type NicA2 enzyme, compositions comprising the variants, and methods using them.
    Type: Application
    Filed: July 2, 2019
    Publication date: February 3, 2022
    Applicant: ANTIDOTE THERAPEUTICS, INC.
    Inventors: Matthew W. KALNIK, Thomas THISTED, Charles C. REED
  • NOVEL NICOTINE-BINDING ANTIBODIES
    Publication number: 20200377616
    Abstract: Described are novel nicotine-binding antibodies and methods of using them for treating nicotine addiction and/or facilitating smoking cessation, or for treating nicotine overdose or nicotine poisoning.
    Type: Application
    Filed: August 14, 2018
    Publication date: December 3, 2020
    Applicants: ANTIDOTE THERAPEUTICS, INC., BliNK BIOMEDICAL, Hennepin Healthcare Research Institute
    Inventors: Matthew W. KALNIK, Thomas THISTED, Nicola BELTRAMINELLI, Stéphanie FALLOT, Zuzana BIESOVA, Steve FULLER, Mark G. LESAGE, Paul PENTEL
  • NOVEL NICOTINE DEGRADING ENZYME VARIANTS
    Publication number: 20200224176
    Abstract: Described are nicotine-degrading enzyme variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity relative to the wild-type NicA2 and NOX enzymes, compositions comprising the variants, and methods using them.
    Type: Application
    Filed: February 2, 2018
    Publication date: July 16, 2020
    Applicants: ANTIDOTE THERAPEUTICS, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Matthew W. KALNIK, Thomas THISTED, Everett STONE, Charles C. REED, Max RODNICK-SMITH
  • NICOTINE-DEGRADING ENZYMES FOR TREATING NICOTINE ADDICTION AND NICOTINE POISONING
    Publication number: 20190015484
    Abstract: Described herein are methods and compositions for treating nicotine addiction, promoting smoking cessation, reducing the risk of relapse of nicotine consumption, and/or treating nicotine poisoning in a subject in need thereof, using a nicotine-degrading enzyme or an expression vector capable of expressing a nicotine-degrading enzyme in vivo.
    Type: Application
    Filed: August 2, 2016
    Publication date: January 17, 2019
    Applicants: The Scripps Research Institute, Antidote Therapeutics, Inc., Antidote Therapeutics, Inc.
    Inventors: Kim D. JANDA, Matt KALNIK, Thomas THISTED